The report covers forecast and analysis for the Parkinsons disease therapeutics market on a global and regional level. The study provides historic data of 2017 along with a forecast from 2018 to 2023 based revenue (USD Billion). The study includes drivers and restraints for the Parkinsons disease therapeutics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Parkinsons disease therapeutics market on a global level.
In order to give the users of this report a comprehensive view on the Parkinsons disease therapeutics market, we have included competitive landscape and analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein drug class segment, route of administration segment and distribution channel segment is benchmarked based on their market size, growth rate, and general attractiveness.
The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions mergers, new technology launch, agreements, partnerships, collaborations joint ventures, research development, technology and regional expansion of major participants involved in the market on the global and regional basis. Moreover, the study covers price trend analysis, the product portfolio of various companies according to the region.
The study provides a decisive view on the Parkinsons disease therapeutics market by segmenting the market based on drug class, route of administration, distribution channel, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2017 to 2023. Based on drug class the market is segmented into levodopa combination, dopamine agonists, monoamine oxidase B (MAO-B) inhibitors, anticholinergic drugs, catechol-o-methyltransferase (COMT) inhibitors and others. Based on rote of administration the market is segmented into the oral, transdermal, subcutaneous, and intestinal infusion. Based on distribution channel the market is segmented into hospital pharmacy, retail pharmacy, and online sales. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and the Middle East Africa with its further bifurcation into major countries. This segmentation includes demand for Parkinsons disease therapeutics market based on individual drug class, and distribution channel in all the regions and countries.
The report also includes detailed profiles of end players such as Novartis AG, F. Hoffmann-La Roche AG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., UCB, Inc., STADA Arzneimittel AG, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Merck Co., Inc., Impax Laboratories, Inc., and Others.
This report segments the global Parkinsons disease therapeutics market as follows:
Global Parkinsons Disease Therapeutics Market: Drug Class Segment Analysis
Levodopa Combination
Dopamine Agonists
Monoamine Oxidase B (Mao-B) Inhibitors
Anticholinergic Drugs
Catechol-O-Methyltransferase (Comt) Inhibitors
Others
Global Parkinsons Disease Therapeutics Market: Route of Administration Segment Analysis
Oral
Transdermal
Subcutaneous
Intestinal Infusion
Global Parkinsons Disease Therapeutics Market: Distribution Channel Segment Analysis
Hospital Pharmacy
Retail Pharmacy
Online Sales
Global Parkinsons Disease Therapeutics Market: Regional Segment Analysis
North America
The U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
Middle East and Africa
